摘要
2013年11月1日美国食品和药物管理局批准奥比妥珠单抗(又名GA101)联合苯丁酸氮芥用于初治的慢性淋巴细胞白血病患者。奥比妥珠单抗是一种经过Fc段修饰的人源糖基化的Ⅱ型抗CD20单克隆抗体,其抗体依赖细胞介导的细胞毒作用及直接细胞毒作用强于利妥昔单抗,补体依赖细胞毒作用弱于利妥昔单抗,药物活性和疗效较高。奥比妥珠单抗具有较好的耐受性,常见的不良事件是输液反应、中性粒细胞减少、血小板减少、贫血、发热等。此外,在治疗CD20阳性非霍奇金淋巴瘤的一系列临床试验中,奥比妥珠单抗也表现出了令人欣喜的结果。
On 1 November obinutuzumab （also known as GA101 ） lymphocytic leukemia. Obinutuzumab 2013, the United States Food and Drug Administration approved for use with chlorambucil in patients with previously untreated chronic is an Fc- glycoengineered humanized type Ⅱ anti- CD20 monoclonal antibody. Compared with rituximab, obinutuzumab shows superior efficacy by inducing direct cell death and enhancing antibody-dependent cellular cytotoxicity with less complement-dependent cytotoxicity. Obinutuzumab has an acceptable and manageable safety profile, the most common adverse reactions of obinutuzumab were： infusion reactions, neutropenia, thrombocytopenia, anemia, pyrexia, cough and musculoskeletal disorder.Several clinical trials have also shown encouraging activity in other CD20^＋ non-Hodgkin＇ s lymphomas.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2015年第8期584-588,共5页
Chinese Journal of New Drugs and Clinical Remedies
